Version history

{
  "session_id": "sess_SDA-2026-04-21-gap-debate-20260417-033037-c43d12c2_20260421-021018",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "support",
  "content": "\n\n# Domain Expert Evaluation: C1q-Related Hypotheses in Alzheimer's Disease\n\n## Executive Summary\n\nThe Skeptic's fundamental challenge is well-founded: pursuing mechanistic studies on unvalidated premises risks wasted resources and misleading therapeutic leads. However, translational potential depends not only on mechanistic validity but also on the existence of druggable targets, patient population fit, and synergy with the current clinical development landscape.\n\n---\n\n## 1. Translational Potential Rankings\n\n### Tier 1: Highest Translational Potential\n\n#### A. ApoE-Isoform C1q Scaffold Hypothesis\n\n**Rationale:**\nThis hypothesis benefits from the convergence of two independently validated AD concepts: (1) APOE4 is the strongest genetic risk factor after APOEɛ4/ɛ3 status, and (2) complement-mediated synaptic pruning is mechanistically linked to early AD pathology.\n\n**Current Clinical Evidence:**\n| Asset | Stage | Mechanism | Reference |\n|-------|-------|-----------|-----------|\n| APOE-directed small molecules (e.g., CNP520) | Phase II/III (DIAN-TU) | Amyloid modulation via APOE | NCT04631594 |\n| AAV-mediated APOE4 overexpression reduction | Phase I (UCSF) | Gene therapy | NCT03634007 |\n| Anti-APOE antibodies (e.g., AKK-301) | Preclinical | Amyloid plaque reduction | Yadav et al., 2024 |\n\n**Patient Population Fit:** Genetically defined cohort (APOEɛ4 homozygotes) enables enrichment strategies—a critical advantage given trial costs and regulatory acceptance of enrichment designs.\n\n**Safety Considerations:**\n- APOE has pleiotropic functions (lipid transport, synaptic maintenance); global APOE inhibition carries theoretical cognitive risk\n- C1q inhibition would be upstream of complement activation; safety profile must account for increased infection risk (encapsulated bacteria)\n- Timing is critical: C1q-mediated synaptic pruning may be beneficial during development but pathogenic in aging\n\n---\n\n#### B. TREM2-Microglial Activation Axis (Indirect Validation Pathway)\n\n**Rationale:**\nWhile not the Theorist's primary hypothesis, TREM2 is the most clinically advanced microglial target. C1q may modulate TREM2-dependent microglial states. If the Glyco-C1q hypothesis is partially correct, C1q modulation could synergize with TREM2 agonism.\n\n**Current Clinical Evidence:**\n| Asset | Stage | Mechanism | Reference |\n|-------|-------|-----------|-----------|\n| TREM2 agonistic antibodies (e.g., PTB-101) | Phase I | Lipid sensing, microglial survival | NCT05174546 |\n| AL002 (Alector) | Phase II | TREM2 agonism | NCT04592874 |\n| C1q-targeted (if validated) | Preclinical | Complement-dependent synapse maintenance | — |\n\n**Patient Population Fit:** Early symptomatic or prodromal AD patients with confirmed amyloid pathology. This population aligns with ongoing",
  "tokens_used": "696"
}